<DOC>
	<DOCNO>NCT00572689</DOCNO>
	<brief_summary>This study do study exenatide , FDA-approved drug lower blood sugar non-pregnant patient type II diabetes , work pregnant woman . To , study drug 's pharmacokinetics ( body drug ; specifically , quickly body break excrete exenatide ) pharmacodynamics ( drug body ; specifically , effectively exenatide help pancreas secrete insulin well control blood sugar meal ) . There two main drug therapy ( insulin injection glyburide pill ) currently use gestational diabetes woman achieve good enough blood sugar control without side effect . Therefore , hope find exenatide might also helpful gestational diabetes .</brief_summary>
	<brief_title>Pilot Study Exenatide Pharmacokinetics Pharmacodynamics Gestational Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes , Gestational</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Pregnant woman ( singleton ) Gestational diabetes require medical therapy Between 18 50 year age Able give write informed consent Women first trim pregnancy Hematocrit le 30 % Current past treatment hypoglycemic agent Women gastrointestinal disease symptom consistent nausea , vomit , abdominal pain reflux require medical treatment . Women high triglyceride level , history gallbladder pancreatic disease . Clinical diagnosis history renal insufficiency ( decreased creatinine clearance )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Exenatide</keyword>
	<keyword>TCF7L2 polymorphism</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>